Tech Company Financing Transactions
AltruBio Funding Round
On 5/21/2024, AltruBio secured $225 million in Series B funding from BVF Partners, aMoon Fund and Blackstone.
Transaction Overview
Company Name
Announced On
5/21/2024
Transaction Type
Venture Equity
Amount
$225,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance the clinical development of its immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268, and to support ongoing and planned Phase 2 clinical trials in ulcerative colitis (UC).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
555 Twin Dolphin Dr. 310
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Website
Email Address
Overview
AltruBio is developing first-in-class immune-modulators to target diseases of the immune system. Its world-class global team brings a breadth of expertise in immunology and drug development to bring their biologic treatments to patients. AltruBio has clinically validated a first-in-class immune checkpoint regulator to selectively target unwanted T-cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Judy Chou
President
Shih-Yao Lin
VP - Administration
Leewen Lin
VP - Bus. Development
Joseph McCracken
VP - Human Resources
Steve Flint
VP - Operations
Simona Reed
Browse more venture capital transactions:
Prev: 5/21/2024: Circtec venture capital transaction
Next: 5/21/2024: Cellugy venture capital transaction
Share this article
About Database of VC Transactions
We report on tech company VC transactions. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs